Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655130 in fistulizing Crohn's disease
NL-OMON55434Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of spesolimab in Crohn's disease, sponsored by Boehringer Ingelheim. Started Jan 2020; status: completed.
02
Drugs
spesolimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON55434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55434.